Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The impact of the COVID-19 pandemic on perioperative chemotherapy for breast cancer.
Baba K, Kawamoto M, Mamishin K, Uematsu M, Kiyohara H, Hirota A, Takahashi N, Fukuda M, Kusuhara S, Nakajima H, Funasaka C, Nakao T, Kondoh C, Harano K, Matsubara N, Naito Y, Hosono A, Kawasaki T, Mukohara T. Baba K, et al. Among authors: kusuhara s. Cancer Med. 2023 Jun;12(11):12095-12105. doi: 10.1002/cam4.5898. Epub 2023 Apr 3. Cancer Med. 2023. PMID: 37012214 Free PMC article.
Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
Uematsu M, Nakajima H, Hosono A, Kiyohara H, Hirota A, Takahashi N, Fukuda M, Kusuhara S, Nakao T, Funasaka C, Kondoh C, Harano K, Matsubara N, Naito Y, Akimoto T, Mukohara T. Uematsu M, et al. Among authors: kusuhara s. Melanoma Res. 2023 Dec 1;33(6):547-552. doi: 10.1097/CMR.0000000000000924. Epub 2023 Sep 4. Melanoma Res. 2023. PMID: 37696254
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study.
Matsubara N, Kusuhara S, Yamamoto N, Sudo K, Yanagita M, Murayama K, Kawasumi H, Russell DL, Yin D, Shimizu T. Matsubara N, et al. Among authors: kusuhara s. Cancer Chemother Pharmacol. 2024 Apr;93(4):341-352. doi: 10.1007/s00280-023-04605-9. Epub 2023 Dec 13. Cancer Chemother Pharmacol. 2024. PMID: 38086998 Free PMC article.
Real-World Outcomes of Different Types of Treatment for Diabetic Macular Edema Before and After Approval of Anti-Vascular Endothelium Growth Factor Agents.
Sugimoto M, Chujo S, Kato K, Shimura M, Kitano S, Kusuhara S, Terasaki H, Kondo M, Writing Committee Of Japan-Clinical Retina Study Group J-Crest. Sugimoto M, et al. Among authors: kusuhara s. J Clin Med. 2024 Dec 2;13(23):7336. doi: 10.3390/jcm13237336. J Clin Med. 2024. PMID: 39685795 Free PMC article.
Use of immunomodulatory treatment for non-infectious uveitis: an International Ocular Inflammation Society report of real-world practice.
Branford JA, Bodaghi B, Ferreira LB, McCluskey PJ, Thorne JE, Matthews JM; International Study Group for Systemic Immunomodulatory Drug Treatment of Non‐Infectious Uveitis; Smith JR. Branford JA, et al. Br J Ophthalmol. 2024 Nov 1:bjo-2024-326239. doi: 10.1136/bjo-2024-326239. Online ahead of print. Br J Ophthalmol. 2024. PMID: 39472042
ALTERATION OF TREATMENT CHOICES AND THE VISUAL PROGNOSIS FOR DIABETIC MACULAR EDEMA IN THE ERA OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR DRUGS: Analysis of the STREAT-DME 2 Study.
Shimura M, Hirano T, Tsuiki E, Takamura Y, Morizane Y, Akiyama K, Yamamoto K, Hikichi T, Koto T, Kinoshita T, Kusuhara S, Yoshida S, Sakamoto SI, Kimura K, Sugimoto M, Kida T, Mitamura Y, Takatsuna Y, Washio N, Osaka R, Ueda T, Minamoto A, Kogo J, Okamoto F, Enaida H, Sakanishi Y, Nagaoka T, Gomi F, Sasaki M, Terasaki H, Iwase T, Tatsumi T, Nishi K, Shinoda K, Ueda S, Ueda-Consolvo T, Nakashizuka H, Murata T, Kitano S, Sakamoto T; J-CREST STREAT-DME 2 Study Group. Shimura M, et al. Among authors: kusuhara s. Retina. 2025 Feb 1;45(2):335-344. doi: 10.1097/IAE.0000000000004301. Retina. 2025. PMID: 39423137 Free PMC article.
192 results